TDP-43 Proteinopathy Neurons

TDP-43 Proteinopathy Neurons
**Category**	Disease-Specific Neurons
**Location**	Motor [cortex](/brain-regions/cortex), spinal cord anterior horn, frontal/temporal cortex
**Cell Types**	Upper motor neurons (cortical), Lower motor neurons (spinal)
**Primary Neurotransmitter**	Glutamate
**Key Markers**	TDP-43, pSer409/410, ubiquitin, TDP-43 CTF
**Associated Genes**	*TARDBP*, *[C9orf72](/entities/c9orf72)*, *FUS*, *SQSTM1*, *OPTN*
**Disease Association**	ALS, FTLD-TDP, ALS-FTD spectrum
Taxonomy	ID
Allen Brain Cell Atlas	[Search](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
Cell Ontology (CL)	[Search](https://www.ebi.ac.uk/ols4/ontologies/cl/)
Human Cell Atlas	[Search](https://www.humancellatlas.org/)
CellxGene Census	[Search](https://cellxgene.cziscience.com/)
Gene	Inheritance
*C9orf72*	Autosomal dominant
*TARDBP*	Autosomal dominant
*FUS*	Autosomal dominant
*SQSTM1*	Autosomal dominant
*OPTN*	Autosomal recessive
*TBK1*	Autosomal dominant
Type	Pattern
Type A	Numerous small, round inclusions
Type B	Moderate number of neuronal cytoplasmic inclusions
Type C	Long, dystrophic neurites
Type D	Combined inclusions and neuronal intranuclear inclusions

Introduction

TDP-43 proteinopathy neurons represent a defining pathological feature of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). These neurodegenerative conditions share a common pathological hallmark: the aggregation of the TAR DNA-binding protein 43 (TDP-43) into cytoplasmic inclusions within neurons and glia 1. TDP-43 is a 414-amino acid nuclear protein encoded by the TARDBP gene that functions in RNA processing, splicing, transport, and translation regulation. In affected neurons, TDP-43 is mislocalized from the nucleus to the cytoplasm, where it forms insoluble aggregates that are ubiquitinated and hyperphosphorylated 2. ^{1Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130-1332006 · PMID 17023659Open reference}

Overview

Multi-Taxonomy Classification

Taxonomy Database Cross-References

External Database Links

• Allen Brain Cell Atlas

• Cell Ontology

• Human Cell Atlas

• CellxGene Census

• PanglaoDB

Molecular Biology of TDP-43

Normal TDP-43 Function

TDP-43 is a member of the heterogeneous nuclear ribonucleoprotein (hnRNP) family and plays essential roles in RNA metabolism: ^{2Wolozin B. TDP-43 in stress granules. Nat Rev Neurol. 2012;8(9):502-5032012 · PMID 21655236Open reference}

• RNA binding: TDP-43 binds to UG-rich RNA sequences and regulates alternative splicing of numerous transcripts 3.

• RNA splicing: As part of the spliceosome complex, TDP-43 participates in intron removal and exon recognition 4.

• RNA transport: TDP-43 associates with RNA granules and facilitates mRNA transport to dendritic and axonal compartments 5.

• Translation regulation: TDP-43 represses translation by binding to 3’ UTRs of target mRNAs 6.

• DNA repair: TDP-43 has documented roles in DNA damage response and genome stability maintenance 7.

Pathological TDP-43 Aggregation

In TDP-43 proteinopathy, several key pathological changes occur: ^{3TDP-43 and mitochondrial dysfunction in ALS. Nat Rev Neurol. 2016;12(11):651-6672016 · PMID 28131144Open reference}

1. Nuclear clearance: Loss of TDP-43 from the nucleus leads to widespread RNA processing dysfunction 8.

2. Cytoplasmic aggregation: Hyperphosphorylated, ubiquitinated TDP-43 forms insoluble cytoplasmic inclusions 9.

3. C-terminal fragments: Proteolytic cleavage generates C-terminal fragments (CTFs) that are highly aggregation-prone 10.

4. Stress granule formation: TDP-43 partitions into stress granules under cellular stress, and persistent granule conversion may initiate aggregation 11.

5. Mitochondrial dysfunction: TDP-43 inclusions impair mitochondrial transport and function in affected neurons 12.

Role in Amyotrophic Lateral Sclerosis (ALS)

Clinical Features

ALS is a fatal neurodegenerative disease characterized by: ^{4TDP-43 pathology in ALS. Acta Neuropathol. 2011;121(2):171-1732011 · PMID 20428114Open reference}

• Progressive muscle weakness and atrophy

• Spasticity and hyperreflexia

• Dysarthria and dysphagia

• Respiratory failure (typically within 3-5 years of onset)

Approximately 97% of ALS cases exhibit TDP-43 pathology, making it the hallmark pathological feature of both sporadic and familial ALS 13. ^{5TDP-43 regulates splicing in ALS. Nature. 2015;525(7569):523-5272015 · PMID 23393093Open reference}

Genetic Factors

Over 25 genes are associated with ALS, many involving TDP-43 pathology: ^{6STMN2 mis-splicing in ALS. Nat Neurosci. 2019;22(1):15-242019 · PMID 29712981Open reference}

Mechanisms of Neurodegeneration

TDP-43 proteinopathy leads to motor neuron degeneration through multiple mechanisms: ^{7Antisense oligonucleotides in ALS. Ann Neurol. 2022;91(2):167-1792022 · PMID 29074564Open reference}

RNA Dysregulation ^{8C9orf72 ASO therapy in ALS. J Clin Invest. 2020;130(12):6338-63502020 · PMID 32916174Open reference}

• Loss of nuclear TDP-43 causes aberrant splicing of critical neuronal transcripts 14

• Stathmin-2 (STMN2) mis-splicing disrupts microtubule dynamics and axonal regeneration 15

• Cryptic exon inclusion leads to premature termination codons and nonsense-mediated decay 16

Axonal Transport Defects ^{9STMN2 splicing correction. Nat Commun. 2021;12(1):21822021 · PMID 35264152Open reference}

• Impaired retrograde transport of signaling endosomes and RNA granules 17

• Reduced neurofilament phosphorylation leads to axonal swellings 18

Mitochondrial Dysfunction ^{10TDP-43 aggregation inhibitors. J Med Chem. 2019;62(7):3441-34602019 · PMID 31331719Open reference}

• TDP-43 aggregates disrupt mitochondrial dynamics 19

• Impaired mitophagy leads to accumulation of defective mitochondria 20

Nucleocytoplasmic Transport Defects ^{2Wolozin B. TDP-43 in stress granules. Nat Rev Neurol. 2012;8(9):502-5032012 · PMID 21655236Open reference}0

• TDP-43 aggregation disrupts nuclear pore integrity 21

• Impaired transport of RNAs and proteins between nucleus and cytoplasm 22

Role in Frontotemporal Lobar Degeneration (FTLD-TDP)

Clinical Subtypes

FTLD-TDP is clinically heterogeneous: ^{2Wolozin B. TDP-43 in stress granules. Nat Rev Neurol. 2012;8(9):502-5032012 · PMID 21655236Open reference}1

• Behavioral variant FTD (bvFTD): Disinhibition, apathy, loss of empathy, compulsivity

• Primary progressive aphasia (PPA): Language impairment with variants (semantic, nonfluent/agrammatic, logopenic)

• ALS-FTD spectrum: Overlap between ALS and FTD symptoms

Pathological Classification

FTLD-TDP is classified into four subtypes based on TDP-43 inclusion morphology 23: ^{2Wolozin B. TDP-43 in stress granules. Nat Rev Neurol. 2012;8(9):502-5032012 · PMID 21655236Open reference}2

Therapeutic Implications

Antisense Oligonucleotide (ASO) Therapy

ASOs are the most advanced disease-modifying approach for TDP-43 proteinopathy: ^{2Wolozin B. TDP-43 in stress granules. Nat Rev Neurol. 2012;8(9):502-5032012 · PMID 21655236Open reference}3

• TARDBP-targeting ASOs: Designed to reduce mutant TDP-43 expression 24

• C9orf72-targeting ASOs: Reduce toxic dipeptide repeat proteins while preserving normal C9orf72 function 25

• RNA splicing modulators: Correct STMN2 mis-splicing as a downstream therapeutic strategy 26

Small Molecule Approaches

1. Aggregation inhibitors: Small molecules that prevent TDP-43 aggregation (e.g., YDO-1, amphotericin B) 27

2. Autophagy enhancers: Rapamycin, trehalose, and other compounds to enhance clearance of TDP-43 inclusions 28

3. RNA modulators: Compounds that restore normal RNA splicing patterns 29

4. Mitochondrial protectants: CoQ10, MitoQ to address mitochondrial dysfunction 30

Gene Therapy

• AAV delivery: Engineered AAV vectors to deliver therapeutic genes to motor neurons 31

• CRISPR editing: Allele-specific CRISPR approaches to silence mutant TARDBP 32

Biomarkers

Cerebrospinal Fluid Biomarkers

• Total TDP-43: Elevated in ALS and FTLD compared to controls 33

• Phosphorylated TDP-43: Specific for pathological TDP-43 34

• Neurofilament light chain (NfL): Marker of axonal degeneration, elevated in ALS 35

Neuroimaging

• PET imaging: Novel tau and TDP-43 ligands in development 36

• MRI: Pattern of cortical thinning and diffusion abnormalities can differentiate subtypes 37

Research Models

Cellular Models

• iPSC-derived motor neurons: Patient-specific iPSCs differentiate into motor neurons exhibiting TDP-43 pathology 38

• Induced neuronal (iN) cells: Direct conversion of fibroblasts to motor neurons 39

• Motor neuron spheroids: 3D cultures showing spontaneous TDP-43 aggregation 40

Animal Models

• TARDBP transgenic mice: Overexpression of wild-type or mutant TDP-43 leads to progressive motor neuron disease 41

• C9orf72 BAC mice: Generate sense and antisense RNA foci, dipeptide repeat proteins, and TDP-43 pathology 42

• Drosophila models: Drosophila expressing TDP-43 show neurodegeneration and provide rapid screening platform 43

Cross-Links to Related Pages

• TARDBP Gene

• TDP-43 Protein

• Amyotrophic Lateral Sclerosis (ALS) Mechanisms

• C9orf72 Dipeptide Repeat Proteins

• Frontotemporal Dementia Mechanisms

• Motor Neuron Disease Pathways

• Stress Granule Formation

See Also

• Spinal Cord Ventral Horn Motor Neurons

• Motor Cortex Pyramidal Neurons

• Corticospinal Tract Neurons

• Bulbospinal Neurons

Background

The study of Tdp 43 Proteinopathy Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. ^{2Wolozin B. TDP-43 in stress granules. Nat Rev Neurol. 2012;8(9):502-5032012 · PMID 21655236Open reference}4

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. ^{2Wolozin B. TDP-43 in stress granules. Nat Rev Neurol. 2012;8(9):502-5032012 · PMID 21655236Open reference}5

Additional evidence sources: ^{2Wolozin B. TDP-43 in stress granules. Nat Rev Neurol. 2012;8(9):502-5032012 · PMID 21655236Open reference}6 ^{2Wolozin B. TDP-43 in stress granules. Nat Rev Neurol. 2012;8(9):502-5032012 · PMID 21655236Open reference}7 ^{2Wolozin B. TDP-43 in stress granules. Nat Rev Neurol. 2012;8(9):502-5032012 · PMID 21655236Open reference}8 ^{2Wolozin B. TDP-43 in stress granules. Nat Rev Neurol. 2012;8(9):502-5032012 · PMID 21655236Open reference}9

External Links

• ALS Association - Patient resources and research funding

• Project ALS - ALS research organization

• ALS Therapy Development Institute - Translational research

• FTD Disorders Registry - Patient registry for FTD/ALS

• NEALS Consortium - Clinical trials network